KRAS and colorectal carcinoma: These mutations are known predictive biomarkers of resistance in metastatic CRC to anti-EGFR therapy, such as cetuximab or panitumumab, and consequently patients whose tumors harbor KRAS or NRAS mutations have fewer therapeutic options.